title: Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
abstract: CONCLUSIONS
  The ROSE study compared annual infusion with zoledronic acid and weekly generic alendronate. No significant differences in quality of life or health status between treatment groups were observed. Adherence to alendronate during the study was high, with 80.9% of patients achieving adequate adherence.
  
  
  BACKGROUND
  A secondary analysis to evaluate quality of life, health status, adherence to alendronate and therapy preference in postmenopausal women with low bone mass who received treatment with zoledronic acid or alendronate was conducted.
  
  
  METHODS
  Postmenopausal women with low bone mass were randomised 2:1 to receive an annual infusion of zoledronic acid or weekly oral generic alendronate in this open-label, multicentre study. Changes in quality of life and health status were assessed using questionnaires at baseline and month 12. Adherence to alendronate was assessed by the investigator and/or study personnel, and subjective therapy preference was assessed using a questionnaire at month 12.
  
  
  RESULTS
  Patients were randomised to zoledronic acid (n = 408) and alendronate (n = 191). Overall, there were no significant differences in quality of life between zoledronic acid and alendronate. However, improvements in quality of life with zoledronic acid versus alendronate could be detected by posthoc analysis in patients with previous fractures. There were no significant differences in health status between patients receiving zoledronic acid or alendronate. Adherence to alendronate during the study was high, with 80.9% of patients achieving adequate adherence. A total of 81% of patients who had received zoledronic acid indicated that they would prefer to continue with that treatment, and 43% of the patients who received oral alendronate would like to switch to zoledronic acid.
  
  
  CONCLUSIONS
  There were no significant differences in quality of life between patients receiving zoledronic acid or alendronate.
authors.affiliation: Department of Gynaecological Endocrinology, Reproductive Medicine and Osteoporosis, Philipps University, Marburg, Germany. hadji@med.uni-marburg.de
authors.forename: P
authors.initials: P
authors.lastname: Hadji
authors.forename: V
authors.initials: V
authors.lastname: Ziller
authors.forename: D
authors.initials: D
authors.lastname: Gamerdinger
authors.forename: W
authors.initials: W
authors.lastname: Spieler
authors.forename: K
authors.initials: K
authors.lastname: Articus
authors.forename: M
authors.initials: M
authors.lastname: Baier
authors.forename: R
authors.initials: R
authors.lastname: Moericke
authors.forename: P H
authors.initials: PH
authors.lastname: Kann
mesh_terms: D000203:Activities of Daily Living; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016568:Drugs, Generic; D005260:Female; D006304:Health Status; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D055118:Medication Adherence; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000534:rehabilitation; D057240:Patient Preference; D011594:Psychometrics; D011788:Quality of Life; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D016568:Drugs, Generic; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate
references.citation: Dtsch Med Wochenschr. 2006 Jun 2;131(22):1257-62
references.pmid: 16755420
references.citation: Bone. 2007 May;40(5):1238-43
references.pmid: 17347063
references.citation: Curr Med Res Opin. 2005 Dec;21(12):1895-903
references.pmid: 16368038
references.citation: Osteoporos Int. 2010 Nov;21(11):1943-51
references.pmid: 19967338
references.citation: Osteoporos Int. 2007 Aug;18(8):1023-31
references.pmid: 17308956
references.citation: Curr Med Res Opin. 2010 Apr;26(4):777-85
references.pmid: 20095797
references.citation: Curr Med Res Opin. 2010 Mar;26(3):675-81
references.pmid: 20078188
references.citation: Climacteric. 2011 Apr;14(2):228-35
references.pmid: 20964548
references.citation: Maturitas. 2009 Jan 20;62(1):85-90
references.pmid: 19100693
references.citation: Bone. 2007 Jul;41(1):122-8
references.pmid: 17468062
references.citation: JAMA. 1999 Aug 18;282(7):637-45
references.pmid: 10517716
references.citation: N Engl J Med. 2007 May 3;356(18):1809-22
references.pmid: 17476007
references.citation: Clin Interv Aging. 2008;3(2):279-97
references.pmid: 18686751
references.citation: Int J Clin Pract. 2006 Aug;60(8):896-905
references.pmid: 16800837
references.citation: Osteoporos Int. 2004 Feb;15(2):113-9
references.pmid: 14618303
references.citation: Osteoporos Int. 2010 Jan;21(1):145-55
references.pmid: 19459025
references.citation: Br J Clin Pharmacol. 2008 Jul;66(1):117-27
references.pmid: 18460036
references.citation: Osteoporos Int. 2011 Jun;22(6):1725-35
references.pmid: 20827547
references.citation: Osteoporos Int. 2012 Jan;23(1):223-31
references.pmid: 21308365
references.citation: Mayo Clin Proc. 2006 Aug;81(8):1013-22
references.pmid: 16901023
references.citation: Osteoporos Int. 2010 Apr;21(4):679-88
references.pmid: 19572092
references.citation: Osteoporos Int. 2009 Oct;20(10):1633-50
references.pmid: 19421703
references.citation: Osteoporos Int. 2012 Feb;23(2):433-43
references.pmid: 21286686
references.citation: Endocr Pract. 2009 Jul-Aug;15(5):483-93
references.pmid: 19491081
references.citation: Osteoporos Int. 2010 Jan;21(1):61-70
references.pmid: 19504036
references.citation: J Intern Med. 2008 Oct;264(4):315-32
references.pmid: 18823505
references.citation: Lancet. 1996 Dec 7;348(9041):1535-41
references.pmid: 8950879
references.citation: J Bone Miner Res. 2011 May;26(5):984-92
references.pmid: 21542001
references.citation: Endocr Pract. 2006 Sep-Oct;12(5):522-8
references.pmid: 17002926
references.citation: Patient Prefer Adherence. 2009 Nov 03;3:25-30
references.pmid: 19936142
references.citation: Arch Intern Med. 2000 Jan 10;160(1):77-85
references.pmid: 10632308
references.citation: Joint Bone Spine. 2008 May;75(3):303-10
references.pmid: 18069036
references.citation: N Engl J Med. 2007 Nov 1;357(18):1799-809
references.pmid: 17878149
references.citation: Osteoporos Int. 2012 Feb;23(2):625-33
references.pmid: 21442459
references.citation: Osteoporos Int. 2008 Apr;19(4):493-501
references.pmid: 17968611